Direct viral infection of solid tumors can cause tumor cell death, but these techniques offer the opportunity to express exogenous factors to enhance the antitumor response. We investigated the antitumor effects of a herpes simplex virus (HSV) amplicon expressing mouse granulocyte-macrophage colony-stimulating factor (mGM-CSF) using the replication-competent HSV type 1 mutant HF10 as a helper virus. HF10-packaged mGM-CSF-expressing amplicon (mGM-CSF amplicon) was used to infect subcutaneously inoculated murine colorectal tumor cells (CT26 cells) and the antitumor effects were compared to tumors treated with only HF10. The mGM-CSF amplicon efficiently replicated in CT26 cells with similar oncolytic activity to HF10 in vitro. However, when mice subcutaneously inoculated with CT26 cells were intratumorally injected with HF10 or mGM-CSF amplicon, greater tumor regression was seen in mGM-CSF amplicon-treated animals. Furthermore, mGM-CSF amplicon treatment prolonged mouse survival. Immunohistochemical analysis revealed increased inflammatory cell infiltration in the solid tumor in the mGM-CSF amplicon-treated animals. These results suggest that expression of GM-CSF enhances the antitumor effects of HF10, and HF10-packaged GM-CSF-expressing amplicon is a promising agent for the treatment of subcutaneous tumors.
Introduction
Genetically altered, replication-competent viruses have recently been developed and used as novel anticancer agents.
1,2 The use of highly attenuated viruses that selectively replicate in and kill tumor cells is called 'oncolytic viral therapy' or 'oncolytic virotherapy'. Although several different viruses have been used for oncolytic virotherapy, most studies have used herpes simplex virus (HSV) or adenovirus as oncolytic viruses. 3 HSV is particularly appealing as an oncolytic virus. HSV infects a wide range of cells causing degenerative changes and cell death. The virus preferentially replicates in dividing cells, and recombinant virus expressing exogenous genes is relatively easy to produce. Furthermore, the HSV-encoded thymidine kinase can enhance the antitumor effect of virotherapy using a 'suicide gene therapy' approach by treating with the thymidine kinase inhibitor ganciclovir. Currently, a number of oncolytic HSV strains have been developed for oncolytic virotherapy. Among these, G207 4 1716 5-8 and NV1020 9 have been extensively investigated and used in clinical trials.
The combination of oncolytic HSV with chemotherapeutic agents, 10-13 radiation [14] [15] [16] [17] or immunostimulatory cytokines 18 has recently been studied in attempts to increase the efficacy of replication-competent oncolytic HSV. Other approaches using HSV as an antitumor agent have been undertaken including the expression of immunostimulatory cytokines using disabled infectious single cycle (DISC) HSV. 19, 20 Additionally, a mutant HSV encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), 21 and HSV amplicons expressing exogenous genes have also been described. [22] [23] [24] [25] HSV amplicon vectors are plasmids containing an HSV origin of replication and packaging sequence. These vectors replicate in the presence of HSV gene products and are packed together in the HSV virion. 26, 27 Thus, the resultant virus (HSV amplicon) consists of HSV's envelope, tegument and capsid surrounding the viral DNA and recombinant DNA plasmid. GM-CSF is a potent immune stimulator promoting the differentiation of progenitor cells to dendritic cells (DCs), the central antigen-presenting cell responsible for inducing an adaptive immune response. 28, 29 Thus, exogenous expression of GM-CSF by an HSV amplicon could potentially promote the induction of an antitumor immune response to enhance the oncolytic effects of HSV. We previously reported that HF10, a highly attenuated replication-competent HSV mutant, has a potent antitumor effect in various tumor models. [30] [31] [32] [33] [34] Moreover, a phase I/II clinical study was performed examining the oncolytic effects of HF10 on recurrent breast cancer. 35 Therefore, we investigated the ability of an HSV amplicon expressing mouse GM-CSF (mGM-CSF) using replication-competent HF10 as a helper virus to control the growth of mouse colorectal tumor cells in both in vitro and in vivo models.
Materials and methods
Cell lines and virus CT26 cells were obtained from American Type Culture Collection (Rockville, MD). African green monkey kidney cells (Vero and COS-7) were obtained from Riken Cell Bank (Tsukuba, Ibaragi, Japan). CT26 is a colon epithelial tumor induced by intrarectal injections of N-nitroso-N-methylurethane in BALB/c mice. CT26 cells were maintained in RPMI 1640 containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Vero cells were grown in Eagle's minimum essential medium (MEM) containing 5% calf serum and 60 mg/ml kanamycin. COS-7 cells were maintained in Dulbecco's MEM containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. All cells were maintained in a 5% CO 2 humidified incubator at 371C.
HF10 is a non-selected clone derived from the laboratory HSV type 1 (HSV-1) strain HF. 30 The properties of HF10 have been previously described. 30 Briefly, the HF10 genome is characterized by a 3.9 kb deletion in the right end of the unique sequence L (UL)/ internal repeat L (IRL) junction, and a 2.3 kb deletion and extensive gene rearrangements at the left end of the L segment. HF10 was propagated in Vero cells at a multiplicity of infection (MOI) of 0.03 at 371C. Virus titers were determined using plaque assays on Vero cells. mGM-CSF-expressing HSV-1 amplicon vector and amplicon production The mGM-CSF-expressing amplicon vector was constructed as follows. The HSV amplicon plasmid, pHGCX, was obtained from Dr Yoshinaga Saeki (Massachusetts General Hospital, Charlestown, MA). pBluescript SKII þ mGM-CSF vector obtained from Dr Hirofumi Hamada (Sapporo Medical University School of Medicine, Sapporo, Japan) contains the mGM-CSF cDNA between EcoRI and BamHI sites. The mGM-CSF cDNA was isolated using the HindIII and BamHI sites and cloned into the pHGCX vector as a transgene driven by the cytomegalovirus promoter. The mGM-CSF-expressing HSV amplicon vector was designated as pHGCXmGM-CSF. Packaging of the HSV-1 amplicon vector into HSV-1 HF10 virions was performed as follows. COS-7 cells (3 Â 10 5 ) were seeded in a 35 mm dish, and, after an overnight incubation, cells were transfected with 4 mg of pHGCXmGM-CSF or pHGCX using Lipofectamine 2000 (Invitrogen, Carisbad, CA), according to the manufacturer's instructions. Two hours after transfection, the transfected cells were infected with HF10 at MOI 0.3. The HF10-packaged pHGCXmGM-CSF (termed as mGM-CSF amplicon) or HF10-packaged pHGCX (empty amplicon) were harvested when a complete cytopathic effect occurred. After freezing and thawing three times and the elimination of cell debris, the supernatants were collected and stored at À801C. Titers of helper virus particles were determined by plaque assay using Vero cells and expressed as plaque forming units (PFU)/ml. Titers of the mGM-CSF amplicon or empty amplicon were determined by infecting Vero cells with serial dilutions of the amplicon stock in the presence of 10 m ganciclovir. After 24 h, the number of green fluorescent cells was counted using a fluorescence microscope and expressed as transduction units.
Immunoblotting CT26 cells were seeded in 35 mm dishes and infected with HF10, empty amplicon and mGM-CSF amplicon at MOI 1. Cells were incubated for 72 h and supernatants were harvested. After 20 ml of supernatant was mixed with 20 ml of sample buffer containing sodium dodecyl sulfate (SDS), the mixture was heated at 1001C for 2 min and then cooled on ice. A total of 40 ml supernatants were separated by 15% SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Nonspecific binding was blocked overnight at 41C with phosphate-buffered saline with 0.05% Tween 20 (PBS-T) containing 5% skim milk. The membrane was incubated with rabbit anti-mGM-CSF antiserum (Sigma-Aldrich, Saint Louis, MI) for 1 h followed by washing three times in PBS-T. The membrane was then incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antiserum (Biosource International, Camarillo, CA) for 1 h at room temperature. Following three washes with PBS-T, the protein bands were visualized with ECL Western Blotting Analysis System (Amersham Biosciences UK, Little Chalfont, UK) and exposed to Fuji film (Fuji Photo Film, Tokyo, Japan).
In vitro experiments CT26 cells were infected with HF10, empty amplicon (packaged into HF10 virions) or mGM-CSF amplicon (packaged into HF10 virions) at MOI 1 in 35 mm dishes. Transduction units of empty amplicon or mGM-CSF amplicon were 6.01 Â 10 4 and 7.42 Â 10
4
, respectively. After a 1 h-adsorption, the cells were washed with PBS three times and incubated with medium at 371C. CT26 cells were harvested at 3, 8, 24, 48 and 72 h post infection. The concentration of mGM-CSF in culture medium was measured by mGM-CSF enzyme-linked immunosorbent assay (ELISA) (Pierce Biotechnology, Rockford, IL). Virus titers were measured by plaque assay using Vero cells. Cell viability was determined by counting the number of viable cells using trypan blue exclusion and calculated as the percentage of the mock-infected control. All assays were performed in duplicate.
Animal studies
Female BALB/c mice (6 weeks old) purchased from Japan SLC (Shizuoka, Japan) were used in this study. CT26 cells (1 Â 10 6 cells in 100 ml of medium) were inoculated subcutaneously into the lumbar region of the mice. After 3 or 4 days when the size of subcutaneous tumor reached approximately 5 mm, the mice were intratumorally injected with either HF10 (1 Â 10 7 PFU), mGM-CSF amplicon (virus titer; 1 Â 10 7 PFU, transduction unit; 8.13 Â 10 4 ) or medium control (Eagle's MEM containing 5% calf serum) for 5 consecutive days. Tumor growth was determined by measuring the tumor volume (p/6 Â length Â width Â height) until the time of animal death. Survival rates were observed until 90 days post CT26 cell inoculation. Incidentally, the tumor disappeared in one individual within 14 days post inoculation, and this was considered a spontaneous rejection and eliminated from analysis. The tumor volume data were analyzed with one-way analysis of variance (ANOVA) followed by Scheffe's test for multiple comparisons among groups. The survival data were analyzed with the Kaplan-Meier method and the log-rank test. P-values less than 0.05 were considered significant. The present studies were conducted in accordance with guidelines issued by the Animal Center at Nagoya University School of Medicine.
Histologic and immunohistochemistry analysis
Mice were killed at indicated times and tumors were fixed in 10% formalin in PBS. Hematoxylin-eosin staining and immunostaining for HSV-1 antigens were performed, as described previously. 34 
Results

Construction of mGM-CSF amplicon and expression of mGM-CSF
We generated the HSV amplicon vector pHGCXmGM-CSF by inserting the cDNA for mGM-CSF downstream of the cytomegalovirus promoter contained in pHGCX (Figure 1a) . The complete vector, pHGCXmGM-CSF, was packaged into HF10, and Vero cells were infected We next infected CT26 cells with HF10, empty amplicon or mGM-CSF amplicon and examined mGM-CSF expression by both western blotting and ELISA. In mGM-CSF amplicon-infected cells, we detected a 16.1 kDa band consistent in size with mGM-CSF, 72 h after infection (Figure 1b) . No mGM-CSF expression was seen in mock-, HF10-and empty amplicon-treated cells. Additionally, mGM-CSF was detected in the supernatants of mGM-CSF amplicon-infected cells as early as 3 h post infection; mGM-CSF levels reached 3000 pg/ml by 72 h (Figure 1c ). Negligible amounts of mGM-CSF were detected in mock-, HF10-or empty ampliconinfected cell supernatants (Figure 1c ).
Replication and oncolytic activity of mGM-CSF amplicon in mouse colorectal tumor cells We next examined the ability of the mGM-CSF amplicon to replicate in the mouse colorectal tumor cell line CT26. At early time points after infection, the virus titers of both empty-and mGM-CSF amplicon-infected cells were higher than that of HF10-infected cells. However, 24 h post infection, the virus titers reached a plateau, and there was little difference between each treatment (Figure 2a) .
Consistent with the viral titer data, the viability of CT26 cells infected with HF10, empty amplicon and mGM-CSF amplicon declined equally with time ( Figure 2b) . Indeed, under all conditions, the number of surviving cells was less than 10% the number of mocktreated cells by 72 h post infection (Figure 2b) . Thus, there was no difference in the in vitro oncolytic effects of the three viruses.
The therapeutic efficacy of mGM-CSF amplicon in syngeneic subcutaneous tumor models using mouse colorectal tumor cells We next examined the ability of the mGM-CSF amplicon to control tumor cell growth in vivo. Two independent series of experiments were performed. In the first series of experiments, syngeneic BALB/c mice were subcutaneously inoculated with 1 Â 10 6 CT26 cells. The tumors were then injected with HF10 (1 Â 10 6 PFU), empty amplicon expressing only GFP (virus titer: 1 Â 10 6 PFU; amplicon: 6.58 Â 10 4 transduction unit), mGM-CSF amplicon (virus titer: 1 Â 10 6 PFU; amplicon: 8.13 Â 10 4 transduction unit) or an equal volume of MEM containing 5% of calf serum seven times at 3, 5, 7, 9, 11, 13 and 15 days after tumor inoculation. As shown in Figure 3a , the mean volumes of tumors in mice treated with GM-CSF amplicon were significantly smaller than those in other groups of mice, and the differences were statistically significant. In the second series of experiments, titers of HF10 were increased by 10-fold without changing the titers of GM-CFS amplicon (Figure 3b ). Mice were inoculated with 1 Â 10 6 CT26 cells, treated with either HF10 (1 Â 10 7 PFU) or mGM-CSF amplicon (virus titer: 1 Â 10 7 PFU; amplicon: 8.13 Â 10 4 transduction unit) five times at 3, 4, 5, 6 and 7 days after tumor inoculation. Seven days after CT26 inoculation (after four treatments), both HF10-and mGM-CSF amplicon-injected tumors were significantly smaller than non-injected controls (Po0.01). These antitumor effects continued throughout the observation period. At 18 days after tumor inoculation, mice injected with mGM-CSF amplicon had significantly smaller tumors than those injected with HF10 (Po0.05). Thus, our results showed that the mGM-CSF amplicon inhibited tumor growth to a greater extent than HF10. 
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All control-treated mice died within 70 days after CT26 cell inoculation (Figure 4 ), and this corresponded to a 50% survival rate of 49 days by Kaplan-Meier analysis. The comparable 50% survival rate in the HF10 and mGM-CSF amplicon treatment groups were 53 and 58 days, respectively. Although the HF10 treatment failed to prolong animal survival (control group vs HF10, P ¼ 0.0738), mGM-CSF amplicon treatment significantly prolonged the survival period (control group vs mGM-CSF amplicon, Po0.05). One HF10-treated mouse and two mGM-CSF amplicon-treated mice survived throughout the 90-day observation period (Figure 4 ). During the observation period, no mice developed signs of neurologic dysfunction after HF10 or mGM-CSF amplicon treatment.
Histopathologic and immunohistochemical analysis
Mice were subcutaneously inoculated with 1 Â 10 6 CT26 cells, and tumors were injected with HF10 (1 Â 10 7 PFU), mGM-CSF amplicon (virus titer: 1 Â 10 7 PFU; amplicon: 8.13 Â 10 4 transduction unit) or an equal volume of MEM containing 5% of calf serum at 4, 5, 6, 7 and 8 days after inoculation of tumor cells. At 6 and 11 days after tumor inoculation, two mice from each group were killed and their tumors were examined histopathologically. As shown in Figures 5a and b , a number of HSV antigenpositive cells were detected in tumors from HF10-treated mice. At day 11, viral antigen-positive cells were detected around degenerative and necrotic areas of tumors (Figure 5b) . In mGM-CSF amplicon-treated mice, viral antigen-positive cells were detected at day 6, but not at day 11 (data not shown). As expected, we observed extensive tumor cell death and fibrosis in both HF10-and mGM-CSF-treated mice compared to mock-treated mice (Figures 5c-h) . Interestingly, there was a greater degree of inflammatory cell infiltration in and around the tumors injected with the mGM-CSF amplicon compared to those treated with HF10 (Figures 5c-h ). Such enhancement of Tumor size was assessed with micrometer calipers twice per week until the first death occurred. Each symbol and bar represents the mean7s.e. The inset figure provides greater detail of the early time points. The tumor volume data were analyzed with one-way ANOVA followed by Scheffe's test for multiple comparisons among groups. **Po0.01; control vs HF10 and control vs mGM-CSF amplicon. *Po0.05; control vs mGM-CSF amplicon. # Po0.05; HF10 vs mGM-CSF amplicon. ANOVA, analysis of variance; GFP, green fluorescent protein; mGM-CSF, mouse granulocyte-macrophage colony-stimulating factor; MEM, minimum essential medium; PFU, plaque forming unit.
Oncolytic virotherapy with GM-CSF HSV amplicon S-i Kohno et al
922
Cancer Gene Therapy Oncolytic virotherapy with GM-CSF HSV amplicon S-i Kohno et al inflammatory cell infiltration was already observed at day 6 (Figures 5d and e) .
Discussion
A number of cytokines have been investigated for their ability to promote tumor rejection, and GM-CSF is one of the most effective cytokines examined to date. 23, [36] [37] [38] [39] GM-CSF has profound effects on the functions of various leukocytes and can recruit neutrophils, monocytes and lymphocytes to enhance their functions in the host immune responses. GM-CSF can also enhance the adaptive antitumor response by recruiting and activating DCs within the tumor. In the present study, we demonstrate that the expression of mGM-CSF using an HSV amplicon in CT26 tumors enhances the antitumor potential of a replication-competent oncolytic virus HF10. The enhanced suppression of tumor growth as well as enhanced local inflammation was observed even at the very early stage of treatment with the mGM-CSF amplicon, suggesting that the activation of nonspecific antitumor immunity induced by mGM-CSF may be predominantly important for this enhanced suppression of tumor growth at the early stage of treatment.
Two methods are typically used to cause exogenous gene expression, liposome-mediated transfection and viral transduction. The efficiency of liposome transfection varies greatly from cell line to cell line, and it is difficult to induce stable, high-level gene expression using many viral systems. The HSV amplicon system has many advantages including high efficiency, safety and great flexibility. In the amplicon system, a helper virus is usually used to package the amplicons. An efficient helper virus-free amplicon system was recently reported using bacterial artificial chromosomes encoding the HSV genome without the packaging sequences. 40 Such a helper virus-free system could potentially eliminate the numerous HSV-encoded immunomodulatory genes such as ICP47. However, the viral yield is relatively low (less than 10 7 PFU/ml) using this system, and low viral titers may not support a full antitumor effect. On the other hand, in virotherapy using replication-competent HSV, intratumor virus production and oncolysis occur, and low viral titers are less of a concern.
A number of oncolytic HSV strains have been investigated for cancer therapy. Among these, G207, 4 1716 5-7 and NV1020 9 have already been used for clinical trials. In mouse models, HSV strains are classified into three pathogenic phenotypes. 41, 42 Class I strains, including wild-type virus and clinical isolates, cause lethal encephalitis both by the intracerebral and the peripheral routes of infection. Class II strains, including HF10, are highly virulent following intracerebral, but not peripheral, infection. 43 Class III strains, including G207 or NV1020, are not virulent by both routes of infection. Class III HSV strains are suited for the treatment of tumors in the central nervous system, but the oncolytic activity of these strains is substantially reduced limiting their application as a viral vector. HF10 was derived from an in vitro-passaged laboratory strain of HSV-1. 30 The mechanism causing HF10 attenuation is unclear, but HF10 lacks the UL56 gene. UL56 associates with the kinesin motor protein KIF1A, and the absence of UL56 causes decreased pathogenicity without affecting viral replication in tissue culture. [44] [45] [46] Thus, the lack of UL56 may be responsible for the attenuated nature of HF10.
In this study, HF10 was clearly capable of replicating in mouse colorectal tumor cells, and infection with HF10 led to lysis of these cells. Additionally, there were no differences in viral replication or tumor cell lysis following CT26 infection with HF10, empty amplicon and mGM-CSF amplicon. Thus, mGM-CSF does not affect in vitro oncolytic activity. However, when we examined the antitumor effects in vivo, mGM-CSF amplicon treatment caused greater tumor regression than treatment with HF10. Thus, the intratumoral expression of mGM-CSF enhanced the antitumor effects of HF10 in vivo.
Multiple mechanisms are thought to mediate the antitumor effects seen in oncolytic virotherapy using HSV. First, HSV replication is directly oncolytic leading to some tumor cell death. Additionally, HSV infection induces an early innate immune response characterized by natural killer cells, macrophages and/or the production of interferon. Finally, tumor-specific immunity is induced leading to tumor cell killing by cytotoxic T lymphocytes (CTL). Treatment of mice with HF10 significantly prolonged their survival in models of both peritoneal metastasis 31 and superficial bladder cancer. 32 Interestingly, in the peritoneal metastasis model using Colon26 cells, all surviving mice were resistant to rechallenge by the same tumor cells. Thus, HF10 treatment appears to promote the generation of an adaptive immune response with associated immunologic memory. CT26 cells process and present the H2L d -restricted gp70 tumor antigen peptide AH-1, 19 and AH-1 is a dominant epitope for CD8 þ CTL. Toda et al. 47 reported that intratumoral inoculation with oncolytic HSV induces a tumor-specific T-cell response and generates AH-1 peptide-specific CTL activity. In addition, CT26 tumor regression can be induced by intratumoral injection of DISC/mGM-CSF virus. 19 When considered with the present results, it is likely that the intratumor expression of GM-CSF can enhance the subsequent, specific antitumor immune response to promote tumor killing and regression.
Recently, a phase I/II study examining the efficacy of HF10 in six patients with recurrent breast cancer was undertaken. 35 Patients were treated with intratumoral injection with HF10 containing no more than 5 Â 10 5 PFU once a day for 3 days. Adverse events were not observed, and anti-HSV-1 antibody titers did not change during the observation period. One patient having received 5 Â 10 5 PFU per injection experienced nearly 100% cancer cell death in the injected lesion. The present study demonstrated that tumor treatment with the mGM-CSF amplicon significantly prolonged animal survival in a model of subcutaneous tumor growth. Taken together with the phase I/II study of HF10, our results suggest that HF10-packaged GM-CSF-expressing amplicon is a promising agent for the treatment of subcutaneous tumors.
